A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).

Edward B Maldonado W Kimryn Rathmell Geoffrey I Shapiro Naoko Takebe Jordi Rodon Ahnert Devalingam Mahalingam Nikolaos A Trikalinos Arash Rezazadeh Kalebasty Mamta Parikh Scott A Boerner Celene Balido Gregor Krings Timothy F Burns Emily K Bergsland Pamela N Munster Alan Ashworth Patricia M LoRusso Rahul R Aggarwal

Published in: Cancer research communications (2024)

Adavosertib failed to exhibit objective responses in SETD2-altered ccRCC and other solid tumor malignancies though prolonged stable disease was observed in a subset of pts. Combination approaches may yield greater depth of tumor response.

Keyphrases

randomized controlled trial
clinical trial

optical coherence tomography

study protocol

double blind